Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482502 | 0.83 | CA2 (0.45) | CA2CA4NQO2LMNAHSD17B10 | |
| SCHEMBL1119270 | 0.81 | CA2 (0.42) | CA2CA4NOTUMMAPTLMNA | |
| SCHEMBL13807389 | 0.81 | HSD17B10 (0.46) | CA2CA4NOTUMNQO2MAPT | |
| SCHEMBL2398559 | 0.80 | CA2 (0.58) | CA2CA4NQO2MAPTHSD17B10 | |
| SCHEMBL7940113 | 0.79 | NOTUM (0.41) | CA2CA4NOTUMNQO2MAPT | |
| SCHEMBL24252358 | 0.78 | CA2 (0.39) | CA2CA4NOTUMNQO2MAPT | |
| SCHEMBL31063348 | 0.75 | CA2 (0.48) | CA2CA4NQO2MAPTHSD17B10 | |
| SCHEMBL22400411 | 0.75 | NOTUM (0.35) | NOTUMMAPTHTT | |
| SCHEMBL30688789 | 0.75 | NOTUM (0.35) | NOTUMMAPTHTT | |
| SCHEMBL1530384 | 0.74 | CA2 (0.52) | CA2CA4NQO2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2203431-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LAB (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CA2 1429/4885CA4 1762/4885NOTUM 2597/4885 |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CA2 3738/4885CA4 2966/4885NOTUM 2910/4885 |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CA2 1429/4885CA4 1762/4885NOTUM 2597/4885 |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CA2 1429/4885CA4 1762/4885NOTUM 2597/4885 |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CA2 3738/4885CA4 2966/4885NOTUM 2910/4885 |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CA2 3738/4885CA4 2966/4885NOTUM 2910/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CA2 1429/4885CA4 1762/4885NOTUM 2597/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | CA2 1551/4885CA4 1338/4885NOTUM 2549/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CA2 1429/4885CA4 1762/4885NOTUM 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.